Primary risk
Primary risk: cardiovascular strain
Combinations significantly increase cardiac risk.
SuspectedLaden…
3-FPO (3-fluorophenmetrazine) is a research chemical structurally related to phenmetrazine. Its pharmacology is largely uncharacterised; mechanism of action, metabolism, toxicity thresholds, and long-term risks have not been clinically validated. Available information is based on structural analogy and unverified user reports from RC monitoring contexts — not a substitute for pharmacological evidence. The substance is associated with stimulant-class risks: cardiovascular strain (tachycardia, hypertension, hyperthermia), sleep deprivation lasting hours to days, elevated redosing impulse/craving patterns, and unpredictable effect intensity due to unclear pharmacokinetics. The exact DAT/NET activation mode — substrate or inhibitor — is not established. Community signals from RC-monitoring contexts are monitoring indicators only, not validated efficacy or safety data.
Class
Stimulants
Pharmacological context
Mechanism
Vermutlich DAT/NET-Aktivierung (Monoamin-Transporter-Substrat oder...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
High Risk
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Newly emerging RC with stimulant-like profile — cardiovascular risk, no validated human data.
Evidence confidence
Critical risk signals
Combinations significantly increase cardiac risk.
SuspectedFurther risks (class-based)
Combinations significantly increase cardiac risk.
Synapedia is actively monitoring this substance. Data is updated as new signals emerge.
Scientific interpretation
Why is this substance flagged?
This substance is flagged because structural-chemical features indicate a stimulant-like profile. Cardiovascular strain is class-documented. No substance-specific human data are available.
No validated human data exist for this substance. The risk profile is extrapolated from class characteristics. Structural-chemical features may hint at possible mechanisms but do not substitute for substance-specific preclinical or clinical data.
Class-based — no substance-specific primary literature
Where does this assessment come from?
Known — structure-based
Derived from stimulant class profile and structural-chemical features.
Suspected — class-based
Extrapolated from known stimulant profile: catecholamine release, cardiovascular strain.
Unknown — no human data
Substance-specific data on pharmacokinetics, dose range and long-term effects are entirely absent.
Deep-dive intelligence
Community reports and forum discussions exist for this substance. Synapedia treats these as monitoring signals, not verified human data. Reports may be confounded by tolerance, polydrug use and unverified product identities.
Community reports are uncontrolled. It often remains unclear:
Synapedia documents community signals but does not derive dose ranges or equivalences from them.
Receptor Targets
Mechanism of Action
3-FPO acts through the following pharmacological mechanisms:
Designations
Receptor Profile
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulants und Antidepressiva beeinflusst.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Risks & Harm Reduction translation in progress
English prose is being expanded. Safety-critical structured data may still be shown when available.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
Help improve the evidence picture — for emerging RCs, reviewed community signals are especially valuable.
For emerging RCs, reports are reviewed especially cautiously. Claims about identity, strength, effects, and duration remain unverified.
The signal hub collects approved risk signals, experience reports and source leads by relevance.